Therapeutic Response

CD20 + status confers therapeutic sensitivity to Cyclophosphamide in combination with Etoposide, Prednisolone, Rituximab, and Vincristine in patients with Non-Hodgkin Lymphoma.

Statements

Source and description
R-CEOP Therapy - 21 days. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved rituximab in combination with cyclophosphamide, etoposide, prednisolone, and vincristine for reimbursement as a treatment option for the treatment of Non Hodgkin CD20 positive Lymphoma for patients not suitable for anthracycline therapy.